

Amendments to the Claims:

This listing of claims will replace all prior versions and listing of claims in the application.

Listing of Claims:

Claim 1 (original): A pharmaceutical composition for treatment of malignancies which comprises in combination a bisphosphonate and an HMG-CoA reductase inhibitor for simultaneous, sequential or separate use.


Claims 2-4 (canceled)

Claim 5 (original): A method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of a bisphosphonate and an effective amount of an HMG-CoA reductase inhibitor.

Claim 6 (previously presented): A composition according to claim 1, for the inhibition of cancer cell growth or induction cancer cell apoptosis.

Claim 7 (previously presented): A composition according to claim 1, in which the bisphosphonate is an N-bisphosphonate.

Claim 8 (previously presented): A composition according to claim 1, in which the bisphosphonate is a compound of formula I



wherein

X is hydrogen, hydroxyl, amino, alkanoyl, or an amino group substituted by C₁-C₄ alkyl, or alkanoyl;

R is hydrogen or C₁-C₄ alkyl and

Rx is a side chain which contains an optionally substituted amino group, or a nitrogen containing heterocycle (including aromatic nitrogen-containing heterocycles), or a pharmaceutically acceptable salt thereof or any hydrate thereof.

Claim 9 (previously presented): A composition according to claim 1, in which the bisphosphonate is 2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmacologically acceptable salt thereof.

Claim 10 (original): A method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of an HMG-CoA reductase inhibitor.

Claim 11 (previously presented): A method according to claim 10, in which the HMG-CoA reductase inhibitor is a statin.


Claim 12 (original): A method according to claim 11, in which the HMG-CoA reductase inhibitor is fluvastatin or a pharmaceutically acceptable salt of ester thereof.

Claim 13 (previously presented): The method according to claim 5, in which the bisphosphonate is 2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmacologically acceptable salt thereof.

Claim 14 (previously presented): The method according to claim 5 for the inhibition of cancer cell growth or induction cancer cell apoptosis.

Claim 15 (previously presented): The method according to claim 5 in which the bisphosphonate is an N-bisphosphonate.

Claim 16 (previously presented): The method according to claim 5 in which the bisphosphonate is a compound of formula I



wherein

X is hydrogen, hydroxyl, amino, alkanoyl, or an amino group substituted by C₁-C₄ alkyl, or alkanoyl;

R is hydrogen or C₁-C₄ alkyl and

Rx is a side chain which contains an optionally substituted amino group, or a nitrogen containing heterocycle (including aromatic nitrogen-containing heterocycles), or a pharmaceutically acceptable salt thereof or any hydrate thereof.